Laddar...

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

BACKGROUND: Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 diabetes and obesity. They elicit robust improvements in glycemic control and weight loss, combined with cardioprotection in individuals at risk of or with pre-existing cardiovascular disease. These attribute...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Mol Metab
Huvudupphovsmän: Baggio, Laurie L., Drucker, Daniel J.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Elsevier 2020
Ämnen:
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8085566/
https://ncbi.nlm.nih.gov/pubmed/32987188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmet.2020.101090
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!